Olaparib approved in the US (but not yet for prostate cancer)


On Friday this week the U.S. Food and Drug Administration approved a drug known as olaparib (Lynparza®) for the treatment of a very specific form of very late stage ovarian cancer. This may be of interest to some men with late-stage prostate cancer.

As we have previously discussed, some physicians believe that olaparib holds potential in the treatment of late stage forms of prostate cancer, and there are ongoing clinical trials.

Olaparib has actually been approved only for the treatment of women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test (the BRACAnalysis CDx test), who have been treated with three or more prior lines of chemotherapy. The implication is that olaparib may, perhaps, have potential in the treatment of men with similar forms of deleterious or suspected deleterious germline BRCA-mutated advanced prostate cancer. However, for men who think that this may be an appropriate option in their individual case, the wisest course would be to see if you are eligible for inclusion in one of the ongoing clinical trials.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: